Home » NH Angle

October 03. 2013 12:53PM

Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants

Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.

CLICK TO VIEW THE SOURCE MATERIAL

 New Hampshire Events Calendar
  

   » SHARE EVENTS FOR PUBLICATION, IT'S FREE!

Arts and Entertainment
Family, Community and Culture
Outdoors, Sports and Recreation